Opinion|Videos|August 22, 2024
CAR T-cell therapy in MM: Updated Data and the Future
Author(s)Rafael Fonseca, MD, Binod Dhakal, MD, MS
Experts provide concluding insights on CAR-T cell therapy and offer their perspectives on the evolving treatment landscape for multiple myeloma, highlighting potential future directions and innovations in patient care.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are your thoughts on the data from:
- CARTITUDE-2: Cohort A
- CARTITUDE 2: Cohort D
- KarMMa-2: Cohort 2B
- Where do you see CAR T-cell therapy in the future of R/R MM?
Advertisement
Related to this article
In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Advertisement
Advertisement
Trending on CancerNetwork
1
Azacitidine Plus Ruxolitinib Shows Durable Responses in Myelofibrosis
2
Defining the Optimal Window for Cytoreductive SABR in Metastatic Kidney Cancer
3
Rusfertide Improves Hematocrit Control vs Placebo in Polycythemia Vera
4
Building Systems to Catch Liver and Other Cancers in Patients With MASLD
5